What is GenoME Diagnostics?
GenoME Diagnostics is a biotechnology firm specializing in the development of groundbreaking blood tests designed for the earlier and more precise diagnosis of ovarian cancer. As a spinout from QUEEN'S University, the company leverages cutting-edge research to create diagnostic solutions that aim to significantly improve patient prognoses. Headquartered in Belfast, Northern Ireland, GenoME Diagnostics is positioned at the forefront of molecular diagnostics, seeking to address a critical unmet need in women's health.
How much funding has GenoME Diagnostics raised?
GenoME Diagnostics has raised a total of $2M across 2 funding rounds:
Angel/Seed
$424K
Other Financing Round
$1.6M
Angel/Seed (2021): $424K with participation from Co-Fund NI, Deepbridge Capital, and QUBIS
Other Financing Round (2023): $1.6M led by Deepbridge Capital and QUBIS
Key Investors in GenoME Diagnostics
Deepbridge Capital
Deepbridge Capital is a venture capital firm that specializes in investing in early-stage, high-growth technology and life science companies. They provide crucial funding and strategic support to help innovative businesses scale and achieve their market potential.
QUBIS
QUBIS is an investment company focused on commercializing research from Queen's University Belfast. They support the creation and growth of spinout companies in sectors like life sciences and technology, providing capital and expertise to foster innovation.
Co-Fund NI
Co-Fund NI is an investment fund dedicated to supporting Northern Ireland's high-growth potential businesses. They provide crucial capital to help companies expand, innovate, and create economic value within the region.
What's next for GenoME Diagnostics?
The substantial enterprise-level capital infusion and recent strategic investment indicate that GenoME Diagnostics is poised for significant scaling and market penetration. This funding is expected to accelerate the company's research and development efforts, potentially expanding its diagnostic pipeline beyond ovarian cancer. Furthermore, the backing from prominent investors suggests a strategic focus on clinical validation, regulatory approvals, and the commercialization of its proprietary technologies. GenoME Diagnostics is likely to enhance its operational capacity and expand its market reach, solidifying its position as a leader in early disease detection.
See full GenoME Diagnostics company page
